GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers

Sulfonylureas (SUs) provide an efficacious first-line treatment in patients with hepatocyte nuclear factor 1α (HNF1A) diabetes, but SUs have limitations due to risk of hypoglycemia. Treatment based on the incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (G...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Diabetes
Glavni autori: Christensen, Alexander S., Hædersdal, Sofie, Storgaard, Heidi, Rose, Kathrine, Hansen, Nina L., Holst, Jens J., Hansen, Torben, Knop, Filip K., Vilsbøll, Tina
Format: Artigo
Jezik:Inglês
Izdano: American Diabetes Association 2020
Teme:
Pharmacology and Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7458039/
https://ncbi.nlm.nih.gov/pubmed/32518064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db20-0074
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items